Stockscreener 앱 받기
26.36
3.10%
0.82
전일 마감가:
$25.54
열려 있는:
$25.64
하루 거래량:
368.77K
Relative Volume:
0.51
시가총액:
$2.22B
수익:
$23.38M
순이익/손실:
$-155.22M
주가수익비율:
-18.18
EPS:
-1.45
순현금흐름:
$-134.36M
1주 성능:
-10.65%
1개월 성능:
-14.73%
6개월 성능:
-35.78%
1년 성능:
-13.67%
1일 변동 폭
$25.20
$26.39
1주일 범위
$25.20
$29.84
52주 변동 폭
$25.20
$47.73
Ideaya Biosciences Inc Stock (IDYA) Company Profile
명칭
Ideaya Biosciences Inc
전화
650-443-6209
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
IDYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| IDYA | 26.36 | 2.22B | 23.38M | -155.22M | -134.36M | -1.45 |
| VRTX | 450.75 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 754.66 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.03 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.35 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-08 | 개시 | SVB Securities | Outperform |
| 2023-05-24 | 개시 | Goldman | Buy |
| 2023-04-24 | 업그레이드 | Stifel | Hold → Buy |
| 2023-03-23 | 개시 | Berenberg | Buy |
| 2023-02-28 | 개시 | RBC Capital Mkts | Outperform |
| 2022-12-28 | 개시 | CapitalOne | Overweight |
| 2022-10-27 | 개시 | Citigroup | Buy |
| 2022-08-15 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-10 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-03-11 | 개시 | Guggenheim | Buy |
| 2020-10-07 | 개시 | Wedbush | Outperform |
| 2020-09-01 | 개시 | Northland Capital | Outperform |
| 2020-07-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-06-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-06 | 개시 | H.C. Wainwright | Buy |
| 2020-03-13 | 개시 | ROTH Capital | Buy |
| 2019-10-17 | 개시 | Oppenheimer | Outperform |
| 2019-09-10 | 개시 | Robert W. Baird | Outperform |
| 2019-06-17 | 개시 | Citigroup | Buy |
| 2019-06-17 | 개시 | JP Morgan | Neutral |
| 2019-06-17 | 개시 | Jefferies | Buy |
모두보기
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
Quest Partners LLC Purchases 32,884 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Finansavisen - Finansavisen
IDEAYA Biosciences (NASDAQ:IDYA) Earns Overweight Rating from Analysts at Stephens - MarketBeat
Ideaya Biosciences Names Chief Commercial Officer - Contract Pharma
IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer - Marketscreener.com
Stephens & Co. Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation - MSN
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year LowTime to Sell? - MarketBeat
Ideaya Biosciences stock hits 52-week low at $27.51 - Investing.com India
500: Something went wrong - Investing.com Canada
Ideaya Biosciences stock hits 52-week low at $27.51 By Investing.com - Investing.com UK
Janus Henderson Group PLC's Strategic Acquisition in IDEAYA Bios - GuruFocus.com
IDEAYA Biosciences' SWOT analysis: biotech stock's potential in uveal melanoma treatment - Investing.com Australia
(IDYA) Investment Analysis - Stock Traders Daily
FMR LLC's Strategic Acquisition of IDEAYA Biosciences Inc Shares - GuruFocus.com
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise - 뉴스와이어
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day - BioSpace
IDEAYA Biosciences Announces Participation Jefferies London | Trending From Our Network - Chicago Star Media
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - The Malaysian Reserve
Ideaya nominates B7H3/PTK7 bispecific ADC as development candidate - BioWorld Online
IDEAYA Announces Development Candidate Nomination of IDE034 | Trending From Our Network - Chicago Star Media
Fiera Capital Corp Sells 45,590 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Research Analysts Set Expectations for IDYA FY2024 Earnings - MarketBeat
90,000 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Purchased by General American Investors Co. Inc. - MarketBeat
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know - Yahoo Finance
The 3.2% return this week takes IDEAYA Biosciences' (NASDAQ:IDYA) shareholders five-year gains to 258% - Simply Wall St
Leerink Partnrs Issues Optimistic Estimate for IDYA Earnings - MarketBeat
FY2024 EPS Forecast for IDEAYA Biosciences Raised by Analyst - MarketBeat
Leerink Partnrs Downgrades IDEAYA Biosciences (NASDAQ:IDYA) to Hold - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 4.5%Here's Why - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to Market Perform at Leerink Partners - MarketBeat
IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023) - Yahoo Finance
Wedbush Reiterates "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences: Q3 2024 Financial and Clinical Progress - TipRanks
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire
abrdn plc Buys Shares of 232,830 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 By Investing.com - Investing.com South Africa
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowHere's What Happened - MarketBeat
Ideaya Biosciences stock hits 52-week low at $28.04 - Investing.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Financial Times
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinic - GuruFocus.com
Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline - MSN
IDEAYA Biosciences' (IDYA) "Outperform" Rating Reaffirmed at Oppenheimer - MarketBeat
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - The Malaysian Reserve
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors – Company AnnouncementFT.com - Financial Times
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase D - GuruFocus.com
WRN inhibitor IDE-275 gains IND clearance for phase I study in MSI-high tumors - BioWorld Online
IDEAYA Biosciences Reports Encouraging Clinical Data for IDE397 in MTAP-Deletion Urothelial Cancer and NSCLC - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $55.45 Average Price Target from Brokerages - MarketBeat
IDYAIDEAYA Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Ideaya Biosciences Inc (IDYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):